The consensus estimate for Q1 2026 revenue is $19.24 million, and the earnings are expected to come in at -$0.24 per share. The full year 2026's revenue is expected to be $76.64 million, and the ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has ADC Therapeutics SA (ADCT) been one of those stocks this ...

View ADC Therapeutics Ltd ADCT stock quote prices, financial information, real-time forecasts, and company news from CNN.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

The average one-year price target for Adc Therapeutics (NYSE:ADCT) has been revised to 8.77 / share. This is an increase of 9.79% from the prior estimate of 7.99 dated October 4, 2023. The price ...

ADCs are a promising development in cancer treatment, targeting specific tumors with minimal side effects. ADCT's first drug, Zynlonta, was approved for third line treatment of lymphoma, but a halted ...

Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...

ADC Therapeutics (ADCT) is scheduled to report earnings on November 7, 2024. The last reported earnings were for reported on August 6, 2024 for Q2.

ADC Therapeutics has raised $200 million (€170 million), bringing its total haul up to $455 million. The antibody-drug conjugate (ADC) specialist will use the money to take its two lead hematological ...